Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

M
Michael Ferguson, MD

Primary Investigator

Overview

The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

Description

The purpose of this clinical research study is to find out if the drugs dabrafenib and trametinib are safe and beneficial in people with BRAF mutation positive LGG or relapsed or refractory BRAF mutation positive HGG.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Low Grade Glioma,High Grade Glioma,BRAF mutation,Low Grade Glioma (LGG),relapsed or refractory High Grade Glioma (HGG), Astrocytoma, Oligodenroglioma, Glioblastoma, Zanthiastrocytoma, Glioma, Gangliocytoma, Neurocytoma, Iponeurocytoma, Papillary Glioneuronal Tumor, Rosette-forming Glioneurona Tumor
  • Age: Between 1 Years - 17 Years
  • Gender: All

Inclusion Criteria


Diagnosis of BRAF V600 mutant High Grade glioma that has relapsed, progressed or failed to respond to frontline therapy

Diagnosis of BRAF V600 mutant Low Grade glioma with progressive disease following surgical excision, or non-surgical candidates with necessity to begin first systemic treatment because of a risk of neurological impairment with progression.

Confirmed measurable disease

Exclusion Criteria

Previous treatment with dabrafenib, trametinib, other RAF inhibitor, other MEK or ERK inhibitor

HGG patient: Cancer treatment within the past 3 weeks.

LGG patient: Any systemic therapy or radiotherapy prior to enrollment

LGG patients: history of allergic reaction or contraindications to the use of carboplatin or vincristine

Stem cell transplant within the past 3 months

History of heart disease

Pregnant or lactating females


Additional Information:
Participants will not be paid for their participation.

Updated on 09 Mar 2024. Study ID: 1803872717 (PHO-FERG-NOVARTIS-36G2201)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center